Video

Dr. Davies discusses data from CheckMate-274 study of nivolumab in urothelial carcinoma

Author(s):

Urology Times staff

"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Benjamin J. Davies, MD, discusses findings from the study, Disease-free survival with longer follow-up from the CheckMate-274 trial of adjuvant nivolumab in patients after surgery for high-risk muscle-invasive urothelial carcinoma, which was presented at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana. Davies is a professor of urology at the University of Pittsburgh School of Medicine, chief of urology at UPMC Shadyside, and program director of the Urologic Oncology Fellowship.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
      Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Margaret Knoedler, MD, on robot-assisted mini-PCNL with the MONARCH Platform
      Margaret Knoedler, MD, on robot-assisted mini-PCNL with the MONARCH Platform
      Khurshid Ghani, MBChB, MS, FRCS, on current barriers to stent omission
      Khurshid Ghani, MBChB, MS, FRCS, on current barriers to stent omission
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Howard Goldman, MD, discusses development of the Glean Urodynamics System
      Howard Goldman, MD, discusses development of the Glean Urodynamics System
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Connor Forbes, MD, on trends in surgical procedures for BPH
      Connor Forbes, MD, on trends in surgical procedures for BPH
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
      Related Content
      From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance
      June 16th 2025

      From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance

      Anne K. Schuckman, MD Hannah Clarke
      Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
      June 12th 2025

      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC

      Hannah Clarke
      The approval is supported by findings from the phase 3 ENVISION trial.
      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
      December 7th 2021

      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

      Urology Times staff
      “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 9th 2025

      En bloc resection of bladder tumor: Is it the way forward?

      Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
      "As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
      Survey: New NMIBC treatments face slow uptake
      June 2nd 2025

      Survey: New NMIBC treatments face slow uptake

      Benjamin P. Saylor
      Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
      © 2025 MJH Life Sciences

      All rights reserved.